Appointments at Euthymics, CytomX, NPS Pharmaceuticals and InQ Biosciences – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Chief scientific officer Biotechnology Medicine

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Euthymics, CytomX, NPS Pharmaceuticals and InQ Biosciences.

Pedro Granadillo ​has been appointed to the board of directors​at NPS Pharmaceuticals​. Granadillo worked at Eli Lilly for 34 years, retiring from the position of senior vice president (SVP) of global manufacturing and human resources in 2004.

Euthymics Bioscience​ has added manufacturing expertise by appointing Walter Piskorski​ as VP, technical operations. Piskorski held similar positions at Orexigen and Sepracor. Earlier in his career Piskorski worked at Baxter and Bristol-Myers Squibb (B-MS).

Mark Rolfe​ has joined CytomX Therapeutics​ as chief scientific officer. Rolfe has more than 20 years of experience in oncology drug discovery and development working at companies including Facet Biotech and Millennium Pharmaceuticals.

CytomX has also hired Henry Lowman ​as VP, research. Lowman joins CytomX from NGM Biopharmaceuticals, where he was director of protein sciences. He also worked at Genentech for 20 years.

InQ Biosciences​ has appointed Michael Chambers ​and John Cooper​ to its board of directors. Chambers is CEO of Swift Biotechnology and helped establish InnoRx Pharmaceuticals. Cooper is the former chairman and CEO of Avocent.

Jasbir Seehra ​has stepped down as chief scientific officer at Acceleron Pharma​. Seehra co-founded Acceleron and has now left to pursue other interests, although he will maintain a consulting relationship.

PolyMedix ​has named Steffen Helming​ as VP of business development. Helming previously worked as EVP, business development at Noxxon Pharma. In this capacity Helming worked with a number of big pharma, including Pfizer, Roche and Eli Lilly.

Kristine Peterson​ has joined the board of directors at Amarin​. Peterson worked at B-MS for 20 years, is the current CEO of Valeritas and has also held positions at Johnson & Johnson and Biovail.

Related topics Markets & Regulations

Related news

Show more